Evidence map›Paper›PMID 41165299›Full record

ArticleHuman vaccines & immunotherapeutics2025

Mapping the evolution of immune checkpoint inhibitor research in small cell lung cancer: A bibliometric analysis (1997-2025).

Ye Chen, Jing Zhu, Jie Wu, Ruhua Fang, Juan Xiong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ye ChenThe Clinical Laboratory Department, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Jing ZhuThe Clinical Laboratory Department, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Jie WuThe Clinical Laboratory Department, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Ruhua FangThe Clinical Laboratory Department, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Juan XiongThe Clinical Laboratory Department, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized small cell lung cancer (SCLC) treatment, yet a comprehensive bibliometric analysis of global research trends is lacking. This study examines publication patterns, key contributors, and emerging research focuses on ICIs in SCLC using bibliometric tools. We analyzed 809 articles from the Web of Science Core Collection (1997-2025) with VOSviewer, CiteSpace, and Bibliometrix. Publications grew at 9.11% annually, with China (304 articles), the USA (201), and Japan (101) as top contributors. Leading institutions included the University of Texas System (105 articles) and UTMD Anderson Cancer Center (84).

Indexed as

BibliometricsBiomedical ResearchImmune Checkpoint InhibitorsLung NeoplasmsSmall Cell Lung CarcinomaHumansImmunotherapyImmune Checkpoint Inhibitorsbibliometric analysisimmune checkpoint inhibitorsimmunotherapySmall cell lung cancer

Identifiers

PMID41165299
PMCPMC12578306

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.